Eisai appoints president of US operations

Share this article:
Eisai president Cynthia Schwalm
Eisai president Cynthia Schwalm

Eisai announced the immediate appointment of Cynthia Schwalm as president of Eisai Inc., a US-based commercial, marketing and sales operation, effective May 5. 

Schwalm will report to Lonnel Coats, president and COO of Eisai Corporation of North America, an umbrella entity that supports the company's various commercial operations in the US, including Eisai Inc. 

“Ms. Schwalm is an exciting addition to our company. She will be instrumental in driving Eisai's integration of MGI PHARMA and strengthening our presence in the US as a top-20 pharmaceutical company,” said Coats in a statement. Eisai completed the acquisition of MGI PHARMA – for $3.9 billion – in January 2008.

Schwalm was previously vice president and general manager of US Oncology Business Unit, at Amgen, Inc.  Before that she worked at various Johnson & Johnson companies, most recently as managing director of Ortho Biotech's offices in the UK and Ireland.

Coats was previously the president and COO at both Eisai Inc. and Eisai Corporation of North America.  With Schwalm as president, Eisai Inc. will no longer have a COO. Coats will retain duties as president and COO at Eisai Corporation of North America.

Share this article:
close

Next Article in News

Email Newsletters

More in News

Lack of marketing partner delays Afrezza launch

Lack of marketing partner delays Afrezza launch

Afrezza was heralded as one of the most innovative diabetes products of the last decade. So, why hasn't MannKind set a firm launch date for the product?

In sunny world of LASIK marketers, a dark underbelly

In sunny world of LASIK marketers, a dark ...

Last week, the former FDA branch chief who originally approved LASIK machines asked FDA to reconsider its denial last month of his petition to ban these devices.

BMS Q2 sales slip, Eliquis, Yervoy soar

BMS Q2 sales slip, Eliquis, Yervoy soar

The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.